Erythropoietin receptor peptide formulations and uses
US7906485B2 · kind B2 · utility
0Cited by
69References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 5, 2006 |
| Grant date | Mar 15, 2011 |
| Priority date | — |
| Expiry date | Sep 16, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including pure red cell aplasia (PRCA). Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.